Summary

According to the recently published report ’Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022’; Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report ’Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022’ outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Discovery stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Undisclosed which include indications Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endocrine Gland Disorders, IgA Nephropathy (Berger’s Disease), Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease) and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

  • The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
  • The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope